Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUSTIN A REYNOLDS

Allopathic & Osteopathic Physicians Internal Medicine Transplant Hepatology

NPI
1568642353
CMS profile
116427
Location
PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$171,401.57

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUSTIN A REYNOLDS

NPI 1568642353 · CMS profile ID 116427

Allopathic & Osteopathic Physicians / Internal Medicine / Transplant Hepatology

PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568642353?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568642353?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568642353?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JUSTIN A REYNOLDS, NPI 1568642353, CMS profile ID 116427, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1568642353?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $171,401.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ipsen Biopharmaceuticals, Inc $42.6710/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208843483 CMS
Gilead Sciences, Inc. $9.1010/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234588822 CMS
Madrigal Pharmaceuticals $47.4810/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302962 CMS
Gilead Sciences, Inc. $33.0010/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373429 CMS
Gilead Sciences, Inc. $24.5010/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373893 CMS
Gilead Sciences, Inc. $18.4410/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234544709 CMS
Novo Nordisk Inc $5,504.8110/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189162778 CMS
Novo Nordisk Inc $24.9010/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189005581 CMS
Gilead Sciences, Inc. $5,150.0009/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234353729 CMS
Madrigal Pharmaceuticals $43.1809/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302956 CMS
Madrigal Pharmaceuticals $126.8409/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302958 CMS
Madrigal Pharmaceuticals $3,878.0009/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302960 CMS
Gilead Sciences, Inc. $6.0309/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234598734 CMS
ABBVIE INC. $16.5809/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203837570 CMS
Gilead Sciences, Inc. $29.3009/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234442543 CMS
Madrigal Pharmaceuticals $127.9409/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302948 CMS
Madrigal Pharmaceuticals $3,878.0009/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302950 CMS
Madrigal Pharmaceuticals $6.0709/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302952 CMS
Madrigal Pharmaceuticals $49.0009/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302954 CMS
Ipsen Biopharmaceuticals, Inc $21.3509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208843463 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $500.0009/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231936797 CMS
Madrigal Pharmaceuticals $48.0209/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302946 CMS
Madrigal Pharmaceuticals $150.0008/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302940 CMS
Madrigal Pharmaceuticals $4,935.0008/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302942 CMS
Madrigal Pharmaceuticals $1,690.5008/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302944 CMS
Gilead Sciences, Inc. $34.0808/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234419775 CMS
Madrigal Pharmaceuticals $145.6008/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302932 CMS
Madrigal Pharmaceuticals $7.4108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302934 CMS
Madrigal Pharmaceuticals $4,935.0008/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302936 CMS
Madrigal Pharmaceuticals $170.1008/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302938 CMS
ABBVIE INC. $18.7608/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203837564 CMS
Madrigal Pharmaceuticals $149.0708/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302926 CMS
Madrigal Pharmaceuticals $3,878.0008/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302928 CMS
Madrigal Pharmaceuticals $32.7608/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302930 CMS
Madrigal Pharmaceuticals $118.7608/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302922 CMS
Madrigal Pharmaceuticals $3,878.0008/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302924 CMS
Madrigal Pharmaceuticals $2.6908/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302920 CMS
Madrigal Pharmaceuticals $85.6208/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302914 CMS
Madrigal Pharmaceuticals $4,935.0008/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302916 CMS
Madrigal Pharmaceuticals $142.8008/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302918 CMS
Madrigal Pharmaceuticals $148.1608/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302906 CMS
Madrigal Pharmaceuticals $3,878.0008/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302908 CMS
Madrigal Pharmaceuticals $3,878.0008/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248302910 CMS
Madrigal Pharmaceuticals $44.8008/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248302912 CMS
Ipsen Biopharmaceuticals, Inc $27.0008/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208843461 CMS
Gilead Sciences, Inc. $11.0208/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234584948 CMS
Madrigal Pharmaceuticals $27.1808/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302904 CMS
Madrigal Pharmaceuticals $21.4407/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302902 CMS
Madrigal Pharmaceuticals $33.2507/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248302900 CMS
Gilead Sciences, Inc. $32.5707/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234425892 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $24,654.03 51
PY2020 $8,000.00 5
PY2021 $8,045.44 20
PY2022 $16,800.13 37
PY2023 $13,699.41 34
PY2024 $68,957.11 122
PY2025 $171,401.57 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $81,427.29 27
PY2024 Principal investigator $188,408.52 34
PY2023 Recipient $1,843.55 17
PY2023 Principal investigator $62,881.00 20
PY2022 Principal investigator $318.00 2
PY2021 Principal investigator $40,114.46 7
PY2020 Principal investigator $84,285.41 13
PY2019 Principal investigator $166,727.36 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,396.50 06/13/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269144
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,729.59 06/11/2025 Non-covered Recipient Entity
ST JOSEPHS PHOENIX
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223281064
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $115.71 06/04/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,660.00 05/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269140
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 05/16/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $665.00 05/16/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269138
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 05/01/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $869.16 05/01/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $566.58 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,154.42 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,800.16 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269118
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269120
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269124
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,899.42 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269126
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269128
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/26/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,064.00 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269108
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $465.50 03/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269112
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $755.44 03/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269104
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,615.00 03/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269106
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $399.00 03/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $66.50 03/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223269102
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,048.87 02/21/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269098
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $234.75 02/19/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,163.19 02/12/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL & MEDICAL CTR
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223269094